Brachytherapy: Current status and future strategies - can high dose rate replace low dose rate and external beam radiotherapy?

Clinical Oncology

Volumn 25, Issue 8, 2013, Pages 474-482

  Morton, G C ^a   Hoskin, P J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Comparative efficacy; External beam; HDR; Image guidance; LDR; Outcomes

Indexed keywords

PALLADIUM 103;

ARTICLE; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CANCER CONTROL; DISEASE FREE SURVIVAL; DOSIMETRY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LOW ENERGY RADIATION; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; URETHRA STRICTURE;

COMPARATIVE EFFICACY; EXTERNAL BEAM; HDR; IMAGE GUIDANCE; LDR; OUTCOMES;

BRACHYTHERAPY; DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 84880585525     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.04.009     Document Type: Article

References (72)

1. Shah C., Lanni T.B.J., Ghilezan M.I., et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 2012, 11:441-445.
2. Viani G.A., da Silva L.G., Stefano E.J. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2012, 83:e619-e625.
3. Grimm P., Billiet I., Bostwick D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012, 109(Suppl. 1):22-29.
4. Holm H.H., Gammelgaard J. Ultrasonically guided precise needle placement in the prostate and the seminal vesicles. JUrol 1981, 125:385-387.
5. Torp-Pedersen S., Holm H.H., Littrup P.J. Transperineal I-125 seed implantation in prostate cancer guided by transrectal ultrasound. Prog Clin Biol Res 1987, 237:143-152.
6. Crook J., Borg J., Evans A., et al. 10-Year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys 2011, 80:1323-1329.
7. Henry A.M., Al-Qaisieh B., Gould K., et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds' 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys 2010, 76:50-56.
8. Hinnen K.A., Battermann J.J., van Roermund J.G., et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:1433-1438.
9. Taira A.V., Merrick G.S., Galbreath R.W., Wallner K.E., Butler W.M. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:349-354.
10. Burri R.J., Ho A.Y., Forsythe K., et al. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:1315-1321.
11. Prada P.J., Juan G., Gonzalez-Suarez H., et al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 2010, 106:32-36.
12. Morris W.J., Keyes M., Spadinger I., et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer 2013, 119(8):1537-1546.
13. Martin A.G., Roy J., Beaulieu L., et al. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 2007, 67:334-341.
14. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. JUrol 2005, 173:1562-1566.
15. Stone N.N., Stone M.M., Rosenstein B.S., Unger P., Stock R.G. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. JUrol 2011, 185:495-500.
16. Sylvester J.E., Grimm P.D., Wong J., et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011, 81:376-381.
17. Lawton C.A., Hunt D., Lee W.R., et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 2011, 81:1-7.
18. Zelefsky M.J., Chou J.F., Pei X., et al. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering Cancer Center experience. Brachytherapy 2012, 11:245-249.
19. Zelefsky M.J., Yamada Y., Pei X., et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011, 77:986-990.
20. Lawton C.A., Yan Y., Lee W.R., et al. Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 2012, 82:e795-e801.
21. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32-43.
22. Critz F.A., Levinson K. 10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. JUrol 2004, 172:2232-2238.
23. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
24. Merrick G.S., Wallner K.E., Butler W.M., et al. 20Gy versus 44Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 2012, 82:e449-e455.
25. Shilkrut M., Merrick G.S., McLaughlin P.W., et al. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer 2013, 119:681-690.
26. Davis B.J., Horwitz E.M., Lee W.R., et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012, 11:6-19.
27. Pieters B.R., de Back D.Z., Koning C.C., Zwinderman A.H. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009, 93:168-173.
28. Shen X., Keith S.W., Mishra M.V., Dicker A.P., Showalter T.N. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012, 83:1154-1159.
29. Mohler J.L., Armstrong A.J., Bahnson R.R., et al. Prostate cancer, Version 3.2012 featured updates to the NCCN guidelines. JNatl Compr Canc Netw 2012, 10:1081-1087.
30. Hoskin P.J., Bownes P.J., Ostler P., Walker K., Bryant L. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 2003, 68:285-288.
31. Holly R., Morton G.C., Sankreacha R., et al. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachytherapy 2011, 10:299-305.
32. Menard C., Susil R.C., Choyke P., et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 2004, 59:1414-1423.
33. Khor R., Duchesne G., Tai K.H., et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:679-685.
34. Cury F.L., Duclos M., Aprikian A., et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results. Int J Radiat Oncol Biol Phys 2012, 82:1417-1423.
35. Martinez-Monge R., Moreno M., Ciervide R., et al. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy inhigh and very high prostate cancer: preliminary data onclinical outcome. Int J Radiat Oncol Biol Phys 2012, 82:e469-e476.
36. Prada P.J., Gonzalez H., Fernandez J., et al. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. BJU Int 2012, 109:1787-1793.
37. Kotecha R., Yamada Y., Pei X., et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013, 12:44-49.
38. Lilleby W., Tafjord G., Raabe N.K. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83:933-939.
39. Kaprealian T., Weinberg V., Speight J.L., et al. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys 2012, 82:222-227.
40. Savdie R., Symons J., Spernat D., et al. High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. BJU Int 2012, 110(Suppl. 4):71-76.
41. Aluwini S., van Rooij P.H., Kirkels W.J., et al. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naive low- and intermediate-risk prostate cancer: a 7-year experience. Int J Radiat Oncol Biol Phys 2012, 83:1480-1485.
42. Whalley D., Patanjali N., Jackson M., et al. HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre. JMed Imaging Radiat Oncol 2012, 56:220-226.
43. Agoston P., Major T., Frohlich G., et al. Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy 2011, 10:376-384.
44. Morton G., Loblaw A., Cheung P., et al. Is single fraction 15cGy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiother Oncol 2011, 100:463-467.
45. Neviani C.B., Miziara M.A., de Andrade Carvalho H. Results of high dose-rate brachytherapy boost before 2D or 3D external beam irradiation for prostate cancer. Radiother Oncol 2011, 98:169-174.
46. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
47. Ghadjar P., Keller T., Rentsch C.A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
48. Pistis F., Guedea F., Pera J., et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 2010, 9:15-22.
49. Zwahlen D.R., Andrianopoulos N., Matheson B., Duchesne G.M., Millar J.L. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy 2010, 9:27-35.
50. Bachand F., Martin A.G., Beaulieu L., Harel F., Vigneault E. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
51. Pellizzon A.C., Fogaroli R.C., Silva M.L., et al. High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control. Int J Clin Exp Med 2011, 4:43-52.
52. Phan T.P., Syed A.M., Puthawala A., Sharma A., Khan F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. JUrol 2007, 177:123-127. discussion 127.
53. Morton G.C., Loblaw D.A., Sankreacha R., et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010, 77:811-817.
54. Yamada Y., Rogers L., Demanes D.J., et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012, 11:20-32.
55. Hoskin P.J., Rojas A.M., Bownes P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103:217-222.
56. Hoskin P., Rojas A., Lowe G., et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012, 82:1376-1384.
57. Prada P.J., Jimenez I., Gonzalez-Suarez H., et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012, 11:105-110.
58. Rogers C.L., Alder S.C., Rogers R.L., et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. JUrol 2012, 187:109-116.
59. Zamboglou N., Tselis N., Baltas D., et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013, 85:672-678.
60. Barkati M., Williams S.G., Foroudi F., et al. High-dose-ratebrachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys 2012, 82:1889-1896.
61. Yoshioka Y., Konishi K., Sumida I., et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011, 80:469-475.
62. Demanes D.J., Martinez A.A., Ghilezan M., et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-1292.
63. Ghilezan M., Martinez A., Gustason G., et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys 2012, 83:927-932.
64. Wang Y., Sankreacha R., Al-Hebshi A., Loblaw A., Morton G. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma. Brachytherapy 2006, 5:251-255.
65. Kovalchuk N., Furutani K.M., Macdonald O.K., Pisansky T.M. Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy. Brachytherapy 2012, 11:111-118.
66. Whitaker M., Hruby G., Lovett A., Patanjali N. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 2011, 101:490-494.
67. Kolkman-Deurloo I.K., Roos M.A., Aluwini S. HDR monotherapy for prostate cancer: a simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation. Radiother Oncol 2011, 98:192-197.
68. Vogelius I.R., Bentzen S.M. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Phys 2013, 85:89-94.
69. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73:1023-1032.
70. Martinez A.A., Demanes J., Vargas C., et al. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33:481-488.
71. Challapalli A., Jones E., Harvey C., Hellawell G.O., Mangar S.A. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol 2012, 85(Spec. no. 1):S18-S27.
72. Morton G.C., Loblaw D.A., Chung H., et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:1299-1305.